CG Oncology (CGON) Valuation Check As Bladder Cancer Trial Timelines Accelerate And Cash Runway Extends To 2029

Simply Wall St.

Mar 02

CG Oncology (CGON) has drawn fresh attention after updating timelines for topline data from key Phase 2 and Phase 3 bladder cancer trials, while also highlighting a cash runway that management expects...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2616532883"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616532883\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616532883?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-02 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616532883","market":"sg","top_or_hot":-1,"title":"CG Oncology (CGON) Valuation Check As Bladder Cancer Trial Timelines Accelerate And Cash Runway Extends To 2029","media":"Simply Wall St.","content":"<div>\n<p>CG Oncology (CGON) has drawn fresh attention after updating timelines for topline data from key Phase 2 and Phase 3 bladder cancer trials, while also highlighting a cash runway that management expects...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-valuation-check-as-bladder-cancer-trial-tim\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CG Oncology (CGON) Valuation Check As Bladder Cancer Trial Timelines Accelerate And Cash Runway Extends To 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCG Oncology (CGON) Valuation Check As Bladder Cancer Trial Timelines Accelerate And Cash Runway Extends To 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-02 21:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-valuation-check-as-bladder-cancer-trial-tim><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CG Oncology (CGON) has drawn fresh attention after updating timelines for topline data from key Phase 2 and Phase 3 bladder cancer trials, while also highlighting a cash runway that management expects...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-valuation-check-as-bladder-cancer-trial-tim\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-valuation-check-as-bladder-cancer-trial-tim","article_id":"2616532883","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-valuation-check-as-bladder-cancer-trial-tim","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616532883","pubTimestamp":1772457660,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CG Oncology (CGON) has drawn fresh attention after updating timelines for topline data from key Phase 2 and Phase 3 bladder cancer trials, while also highlighting a cash runway that management expects will extend into 2029.\nSee our latest analysis for CG Oncology.\nThe recent update on expedited trial timelines and a cash runway into 2029 comes after a strong run in the shares, with the latest close at $58.8, a 90 day share price return of 42.13% and a 1 year total shareholder return of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","CG":"凯雷","BK4135":"资产管理与托管银行","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","CGON":"CG Oncology Inc.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","AAQC":"Accelerate Acquisition Corp"},"translate_title":"随着膀胱癌试验时间表的加快和现金跑道延长至2029年，CG Oncology(CGON)的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"AAQC":1.5,"CGON":1.5,"CG":1.5},"content_text":"CG Oncology (CGON) has drawn fresh attention after updating timelines for topline data from key Phase 2 and Phase 3 bladder cancer trials, while also highlighting a cash runway that management expects will extend into 2029. See our latest analysis for CG Oncology. The recent update on expedited trial timelines and a cash runway into 2029 comes after a strong run in the shares, with the latest close at $58.8, a 90 day share price return of 42.13% and a 1 year total shareholder return of 134.26%. This suggests momentum has been building as investors reassess both progress and risk around the bladder cancer pipeline. If this kind of biotech momentum has your attention, it could be a good time to scan 28 healthcare AI stocks and see which other health focused names are catching interest right now. With shares up strongly and the stock trading at a roughly 37% discount to a US$80.43 analyst target, alongside an intrinsic discount of about 80%, is CG Oncology still mispriced or is the market already baking in future growth? AdvertisementPrice to Book of 6.6x: Is It Justified? On Simply Wall St's numbers, CG Oncology trades at a P/B of 6.6x at the last close of $58.8, sitting between cheaper peers and more expensive close comparables. P/B compares the market value of the company to the accounting value of its net assets. It is often used for early stage or unprofitable biotechs where earnings are not yet a reliable anchor. For CG Oncology, the data suggests a mixed picture. The stock is described as good value against a peer group average P/B of 11.1x, yet expensive relative to the broader US Biotechs industry average of 2.7x. That gap hints that investors are putting a higher tag on its pipeline and trial progress than the typical biotech name, while still paying less than for some closer high priced peers. Compared with the industry, the 6.6x P/B sits at more than double the 2.7x sector average. This is a strong premium and suggests expectations that differ from the wider group. There is no fair ratio estimate available, so there is no statistical anchor for where this multiple could settle based on historical relationships. This leaves the current level dependent on how the story around trials and future cash generation develops. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 6.6x (ABOUT RIGHT) However, results from ongoing trials and the current net loss of $160.995m could quickly challenge the optimism embedded in today’s price to book ratio and discount to targets. Find out about the key risks to this CG Oncology narrative. Another View: What The DCF Model Says While the 6.6x P/B ratio points to a middle ground between cheaper and pricier peers, our DCF model presents a very different picture. On these cash flow assumptions, CG Oncology at $58.8 is trading at roughly an 80% discount to an estimated fair value of $292.05. That gap indicates the market price and the DCF view are far apart, which can signal either a potential opportunity or a sign that the cash flow assumptions are too optimistic. For you as an investor, the central question is which perspective you place more weight on: the balance sheet multiple or the long range cash flow model? Look into how the SWS DCF model arrives at its fair value. CGON Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CG Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Curious whether the optimism in this story outweighs the risks or the other way around? Take a moment to review the numbers yourself and decide how you feel about CG Oncology, then round out your view by checking 2 key rewards and 1 important warning sign. Looking for more investment ideas? If CG Oncology has sparked your interest, do not stop here. The market is full of other opportunities that could suit your style and risk comfort.  Target stability first by checking out 76 resilient stocks with low risk scores that aim to help keep portfolio shocks in check while you focus on the long game. Hunt for value by reviewing screener containing 24 high quality undiscovered gems where strong fundamentals may not yet be fully appreciated by the wider market. Strengthen your core holdings by focusing on companies from our solid balance sheet and fundamentals stocks screener (41 results) that put financial resilience front and center.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}